TNFRSF17 and Miyoshi myopathy: CAR T therapy at this point does not appear to be curative, and relapses may occur due to selection of BCMA-negative MM cells as well as antigen escape via secretion of BCMA into the bloodstream through the action of gamma-secretase (88).